Post
The Wall Street Journal
wsj.com
did:plc:i3fhjvvkbmirhyu4aeihhrnv
The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without relapses follows a rejection from U.S. drug regulators. on.wsj.com/3QlheLD
https://on.wsj.com/3QlheLD
2026-06-23T05:41:28.164Z